Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANGIODYNAMICS INC Director's Dealing 2021

Dec 30, 2021

32939_dirs_2021-12-30_cf2ff7ab-6fd5-4390-9ed9-fa5a1af7c822.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2021-07-14

Reporting Person: Clemmer James C (Director, President and CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-07-21 Common Stock A 37420 Acquired 372503 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-07-21 Performance Right $ A 74840 Acquired Common Stock (74840) Direct
2021-07-21 Non-Qualified Stock Option (right to buy) $26.49 A 101667 Acquired 2031-07-21 Common Stock (101667) Direct

Footnotes

F1: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

F2: The acquisition of 37,420 shares of common stock ("Common Stock") of the Company represents 37,420 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

F3: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F4: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.